IP Library Patent Application 16183638
Patent Application
App. No. 16/183,638

FIXED DOSE COMBINATION FOR PAIN RELIEF WITHOUT EDEMA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/183,638
Abstract

Compositions and methods for individualized therapy of pain using a non-steroidal anti-inflammatory drug (NSAID) and an anti-hypertensive without inducing intolerable edema. Said methods comprise basing NSAID/anti-hypertensive dose on each patient's pharmacokinetic response to said NSAID.

Claims (19)

1 . A method for treating pain in a mammal, comprising:

a. administering or causing to be administered to the mammal celecoxib and lisinopril in a fixed dose combination (FDC);

b. administering the celecoxib and lisinopril to the mammal for a period time sufficient to treat the pain, but not less than sixty (60) days;

wherein, the treatment reduces the incidence of edema in the mammal administered celecoxib and lisinopril as compared to a mammal administered celecoxib alone by at least 17%.

2 . The method of claim 1 , wherein the pain is arthritic pain.

3 . The method of claim 2 , wherein the arthritic pain is osteoarthritic pain.

3 . The method of claim 1 , wherein the composition is in the form of a pill in pill, capsule in capsule,-bilayer tablet or other formulation method with physical separation between celecoxib and lisinopril.

4 . The method of claim 1 , wherein the dose of celecoxib is 50 to 400 mg.

5 . The method of claim 1 , where the dose of lisinopril is 2.5 to 100 mg.

6 . The method of claim 1 , wherein the celecoxib and lisinopril is administered to the mammal orally, rectally, by inhalation, trans-cutaineously, by injection, intravenously or intraarterially.

7 . The method of claim 1 , wherein the celecoxib and lisinopril is provided to the mammal in the form of a tablet, a capsule, a sachet, an orally disintegrating film, a wafer or a long-lasting injectable system.

8 . The method of claim 1 , wherein the celecoxib and lisinopril are administered to the mammal in the form of a capsule, a pill, or a bilayer.

9 . The method of claim 8 , wherein the capsule, the pill, or the bilayer contain an enteric coating.

10 . The method of claim 1 , wherein the dose of celecoxib and lisinopril in a single dosage unit is 100 mg celecoxib and 40 mg lisinopril, 200 mg and celecoxib 40 mg lisinopril, 100 mg celecoxib and 5 mg lisinopril, or 200 mg celecoxib and 5 mg lisinopril.

11 . A method for treating osteoarthritic pain in a mammal, comprising:

a. administering or causing to be administered to the mammal celecoxib and lisinopril in a fixed dose combination (FDC);

b. administering the celecoxib and lisinopril to the mammal for a period time sufficient to treat the pain, but not less than sixty (60) days;

wherein, the treatment reduces the incidence of edema in the mammal administered celecoxib and lisinopril as compared to a mammal administered celecoxib alone by at least 17%.

12 . The method of claim 11 , wherein the dose of celecoxib and lisinopril in a single dosage unit is 100 mg celecoxib and 40 mg lisinopril, 200 mg celecoxib and 40 mg lisinopril, 100 mg celecoxib and 5 mg lisinopril, or 200 mg celecoxib and 5 mg lisinopril.